id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-273151-1h8c4yq9	LOCHT, Camille	Vaccines against COVID-19	2020-10-20		.txt	text/plain	1516	94	51	Several hundred COVID-19-specific vaccines are at various stages of development in academia and industry and make use of a variety of different generic platforms, such as inactivated virus, purified recombinant viral proteins with or without adjuvant, replicating and non-replicating viral vectored antigens, antigen-encoding DNA or mRNA. A phase 1, open-label trial in young adults showed acceptable safety and reactogenicity and the induction of neutralising antibodies after two injections 16 . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomized, first-in-human trial Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults	./cache/cord-273151-1h8c4yq9.txt	./txt/cord-273151-1h8c4yq9.txt